Get started
Author

Sher Gul Gazdar

Observed name: Sher G. Gazdar
ORCID: 0009-0008-2729-2820
Observed ORCID: 0009-0008-2729-2820
OpenAlex ID: A5120635817
Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)
2025 · Matthew Rees, Masa Lasica, et al. · Blood · 3
PDF
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon‐α2b in newly diagnosed chronic phase chronic myeloid leukaemia
2025 · David T. Yeung, Andrew P. Grigg, et al. · British Journal of Haematology · 2
Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 ( SeaLAND ) trial
2026 · Matthew J. Rees, Masa Lasica, et al. · British Journal of Haematology
PDF
Works count: 3
Citation count: 5
H-index: 2
I10-index:
Year
Topic
Type